tbuckley/cabot-search huggingface dataset:
GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis
Authors: M. Larsabal, S. Ly, E. Sbidian, M. Moyal‐Barracco, J.‐N. Dauendorffer, N. Dupin, M.A. Richard, O. Chosidow, M. Beylot‐Barry, Ivana Abdo, Marie Acquitter, Maud Ami Breteque Mignot, Jean‐Michel Amici, Elodie Archier, François Aubin, Hugues Barthelemy, Emilie Baubion, Nathalie Beneton, Cécile Bolac, Danielle Bouilly, Catherine Bourseau‐Quetier, Emilie Brenaut, Christel Buzenet, Magalie Camus, Philippe Celerier, Cécile Chabbert, Mélanie Chamaillard, Sophie Charles, Anne‐Sophie Darrigade, Michele‐Pillette Delarue, Florence Depaire, Suzanne Devaux, Giao Do‐Pham, Anne‐Benedicte Duval‐Modeste, Françoise Fabre, Antoine Fauconneau, Charlotte Fite, Camille Fleuret, Céline Girard, Sophie Grande, Stéphanie Guillet, Florence Hacard, Salama Hegazy, Stéphanie Hosteing, Marie‐Agnès Jacquin, Marie‐Hélène Jegou, Pascal Joly, Thomas Jouary, Denis Julien, Mathilde Kemula, Elise Kostrzewa, Jean‐Philippe Lacour, Valérie Legrain, Cristina Livideanu, Devy Lu, François Maccari, Françoise Magne, Clemmie Martin, Laurent Meunier, Laurent Misery, Josiane Parier, Fabien Pelletier, Marc Perrussel, Antoine Petit‐Fauconneau, Itzia Peyrot, Patrice Plantin, Christelle Pruvost‐Balland, Elodie Regnier, Judith Reynier‐Rezzi, Camille Salzes, Julien Seneschal, Martine Shollhammer, Agathe Souteyrand, Delphine Staumont, Anne Toulemonde, Clelia Vanhaecke, Anne‐Laure Vedie, Julie Versapuech, Martine Vigan, Manuelle Viguier, Axel Villani
Journal: British Journal of Dermatology (2018)

Genital psoriasis is often under-recognized.To assess the instantaneous prevalence of genital psoriasis and describe its clinical features, association with a particular subtype of psoriasis and its impact on general and sexual quality of life (QoL).GENIPSO is a prospective study conducted by private and hospital-based dermatologists. This study featured the consecutive inclusion of patients consulting for extragenital psoriasis. The clinical features of psoriasis and genital psoriasis were recorded and QoL and sexual health questionnaires were distributed to patients.Overall, 335 of 776 patients (43·2%) included in the study had genital involvement. All were aware that they had genital lesions but only 135 patients (40%) declared that they had been previously examined. Genital lesions were associated with male sex, severity of psoriasis, age of onset > 20 years, inverse psoriasis and involvement of scalp, nail and external auditory canal, but were not associated with obesity, psoriatic arthritis and active sex life. Itching was the main symptom. Genital psoriasis was associated with impairment of QoL and sexual health according to the Dermatology Life Quality Index and the Female Sexual Function Index.Genital psoriasis has a high prevalence in patients consulting for extragenital psoriasis, which affects QoL, and should be taken into account by dermatologists in order to optimize global care.
Abstract IA36: Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers
Authors: Sergio Quezada
Journal: Clinical Cancer Research (2018)

Abstract In mice, anti-CTLA-4 monoclonal antibodies (mAbs) require Fc-gamma receptor (FcγR)-mediated depletion of intratumoral regulatory T (Treg) cells to promote tumor rejection. However, the relevance of this mechanism in the human setting remains controversial. Using a mouse model expressing human FcγRs, and analysis of clinical samples from ipilimumab-treated melanoma patients, we investigate the potential role of Treg depletion in the activity of antibodies targeting human CTLA-4. Citation Format: Sergio Quezada. Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr IA36.
Outcome of use of regorafenib in metastatic colorectal cancer in routine clinic practice in Saudi Arabia.
Authors: Ali Husain Aljubran, Muhammad Zahir, Ahmed Gad, Abdelmuniem Al-Dalee, Shouki Bazarbashi, Mahmoud Abdelsatar Elshenawy, Ahmad Al Zahrani
Journal: Journal of Clinical Oncology (2017)

e15021 Background: Regorafenib is a multi-kinase inhibitor that was FDA approved for the treatment of refractory advanced colorectal cancer. It has been found in the clinical trials to have modest benefit and relatively high toxicity, but the outcome of its routine use in the clinic practice is lacking. Our aim is to assess the outcome in our local clinic practice. Methods: Records of all colorectal cases who were treated with regorafenib were reviewed. Structured CRF was developed. Clinical, pathological and molecular data were collected. Efficacy and toxicity details were analyzed. Results: Thirty-two cases of metastatic colorectal cancer were treated with regorafenib from February 2014 to February 2016. All patients received prior oxaliplatin, irinotecan and bevacizumab based regimens, and cetuximab if wild type. Median age: 53.5 years. Male: 15 (46.9%). Primary tumor was right sided in 10 patients (31.3%), and left sided (including rectum) in 22 (68.7%). Pan RAS mutant: 21 (65.6%). Fifteen patients (46.9 %) had ECOG Performance Status of one, whereas 16 patients (50%) have ECOG 2. Starting dose was reduced to 120mg in 11 (34.4%). Only 5 (15.6%) continued beyond 3 cycles. 18 patients (56.3%) required dose reduction. Overall response: PR/CR: zero; Stable disease: 4 (12.5%); Progressive disease: 25 (78.1%); Clinical progression in 1 (3.1%), and 2 cases were not evaluated. After median follow up of 7 months, 22 patients (68.8%) have died, 5 (15.6%) are still alive and 5 (15.6%) are lost to follow up. Median survival: 9.3 months, and median PFS: 2.5 months. Conclusions: Regorafenib has poor tumor response in the routine clinic practice when given to patients with ECOG PS &gt; 1. The median survival in this series is probably overestimated because of the relatively high rate of loss to follow up. Selection of patients is required in the routine clinic practice. Predictive markers are more important for such treatment with modest benefit, and significant toxicity and cost.
Toxicity and efficacy of Palbociclib with endocrine therapy of physician’s choice in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: A single centre experience.
Authors: Nicolo Matteo Luca Battisti, Belinda Kingston, Kabir Mohammed, Stephen R. D. Johnston
Journal: Journal of Clinical Oncology (2018)

e13039 Background: Palbociclib is approved in the UK in first line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Program (CAP) allowed patients to receive it in fourth line based on the PALOMA3 study. However, Palbociclib has not been specifically tested in this population. We determined adverse events (AEs) and clinical benefit rate (CBR) in patients on Palbociclib within the CAP at our Institution, along with progression-free survival (PFS) and overall survival (OS) as secondary endpoints. Methods: We retrospectively identified HR-positive HER2-negative ABC patients on Palbociclib within the CAP between January 2015 and October 2017. Demographics, disease characteristics, prior treatments, blood tests, toxicities, treatment delays and responses were recorded. Simple statistics, Fisher’s exact test, chi-squared method and Cox regression were used as appropriate. Results: 52 patients identified had a median age of 61 (23-82). 40 (76.2%) had visceral involvement, 5 (9.6%) bony only and 4 (7.7%) visceral only. They had a median 5 (range 3-11) prior lines of treatment and 3 (range 0-5) prior chemotherapies. 48 patients (92.3%) developed neutropenia, which was grade 3-4 in 31 (59.6%) and delayed treatment in 34 (70.8%). Grade 3-4 neutropenia occurred in 20 patients (64.5%) who received ≥3 and in 11 (35.5%) who received < 3 prior chemotherapies (p = 0.123). 3 patients experienced febrile neutropenia (5.8%). 23 patients out of 46 assessed (50.0%) had clinical benefit (stable disease or partial response). 46 discontinued treatment, owing to disease progression in 43 (82.7%) and toxicities in 3 (5.8%). Median PFS was 4.5 months (95% CI 3.7-10.1) and higher in patients who had received < 3 lines of chemotherapy (7.6 months, 95% CI 3.7-12.2) than those treated with ≥3 lines (3.9 months, 95% CI 2.9-8.8) (p = 0.61). Median OS was 15.4 months (95% CI 12.0-18.3). Conclusions: Incidence of grade 3-4 neutropenia was similar in this cohort compared to PALOMA trials, albeit febrile neutropenia rates were higher. Clinical benefit was seen in this heavily pretreated population.
Deep‐learning‐based, computer‐aided classifier developed with a small dataset of clinical images surpasses board‐certified dermatologists in skin tumour diagnosis
Authors: Y. Fujisawa, Y. Otomo, Y. Ogata, Y. Nakamura, R. Fujita, Y. Ishitsuka, R. Watanabe, N. Okiyama, K. Ohara, M. Fujimoto
Journal: British Journal of Dermatology (2018)

Application of deep‐learning technology to skin cancer classification can potentially improve the sensitivity and specificity of skin cancer screening, but the number of training images required for such a system is thought to be extremely large. To determine whether deep‐learning technology could be used to develop an efficient skin cancer classification system with a relatively small dataset of clinical images. A deep convolutional neural network (DCNN) was trained using a dataset of 4867 clinical images obtained from 1842 patients diagnosed with skin tumours at the University of Tsukuba Hospital from 2003 to 2016. The images consisted of 14 diagnoses, including both malignant and benign conditions. Its performance was tested against 13 board‐certified dermatologists and nine dermatology trainees. The overall classification accuracy of the trained DCNN was 76·5%. The DCNN achieved 96·3% sensitivity (correctly classified malignant as malignant) and 89·5% specificity (correctly classified benign as benign). Although the accuracy of malignant or benign classification by the board‐certified dermatologists was statistically higher than that of the dermatology trainees (85·3% ± 3·7% and 74·4% ± 6·8%, P < 0·01), the DCNN achieved even greater accuracy, as high as 92·4% ± 2·1% (P < 0·001). We have developed an efficient skin tumour classifier using a DCNN trained on a relatively small dataset. The DCNN classified images of skin tumours more accurately than board‐certified dermatologists. Collectively, the current system may have capabilities for screening purposes in general medical practice, particularly because it requires only a single clinical image for classification.
A novel prognostic risk classification model for NUT midline carcinoma: a largest cohort analysis from the NMC registry.
Authors: Nicole Grace Chau, Clement Ma, Kristina Danga, Hasan Al-Sayegh, Madhumitha Sridharan, Valentina Nardi, Ryan Barrette, Christopher Lathan, Steven G. DuBois, Robert I. Haddad, Geoffrey Shapiro, Stephen E. Sallan, Arindam Dhar, Jeanenne Joy Nelson, Christopher Alexander French
Journal: Journal of Clinical Oncology (2018)

6085 Background: NUT midline carcinoma (NMC) is a rare subtype of squamous cancer defined by rearrangement of the NUT gene. Due to its rarity and under-diagnosis, there are no existing models to classify patients (pts) into risk groups based on baseline clinicopathologic factors. We aim to develop a prognostic risk classification model for NMC survival outcomes based on the largest cohort of NMC pts analyzed to date. Methods: Clinicopathologic variables and survival outcomes were extracted for N = 143 pts registered between 1990-2017 from the International NMC Registry. We performed survival tree regression to determine pt subgroups with statistically distinct risk factors and overall survival (OS) outcomes. Briefly, we performed Cox proportional-hazards regression for each potential factor. We dichotomized pts into two subgroups using the significant factor with the highest hazard ratio. We repeated this process within each subgroup until no further significant factors were found. Results: For N = 143 pts, median diagnosis age was 24 y (range = 18d-80y) and 48% were male. About half (54%) of tumors were without squamous cell differentiation; 54% had thoracic origin, 40% head/neck, and 6% other primary site. Most patients had the BRD4-NUT fusion (71%), followed by BRD3-NUT (13%), and NSD3-NUT (5%). At diagnosis, 78% had lymph node or organ metastases (mets). Median follow-up time was 2.9y (1d-19.1y). For N = 134 with survival data, median OS was 6.8m (95% CI = 5.8-9.7); 2-year OS was only 23% (±SE = ±4%). Survival tree regression identified 3 distinct risk groups: (A) no mets [2-yr OS = 39.5±10%; N = 24]; (B) with mets, non-thoracic origin [2-yr OS = 38.7±10%; N = 27]; (C) with mets, thoracic origin [2-yr OS = 6±4%, N = 55]. Conclusions: This is the first risk classification model for NMC. Metastatic pts with thoracic primary tumors have markedly poorer prognosis compared to other subgroups.
TCT-391 Post-implantation Shear Stress Analysis: An Emerging Tool for Differentiation in Bioresorbable Scaffolds
Authors: Erhan Tenekecioglu, Ryo Torii, Christos Bourantas, Yuki Katagiri, Ply Chichareon, Taku Asano, Rodrigo Modolo, Rasha Al-Lamee, Kadem Al-Lamee, Nial Bullett, Marie-Angele Morel, Yoshinobu Onuma, Patrick Serruys
Journal: Journal of the American College of Cardiology (2018)
Survey results of US radiation oncology providers' contextual engagement of watch-and-wait beliefs after complete clinical response to chemoradiation in patients with local rectal cancer.
Authors: Jehan Yahya, Daniel Herzig, Matthew Farrell, Catherine Degnin, Yiyi Chen, John M. Holland, Simon Brown, Christina Binder, Jerry Jeff Jaboin, Vassiliki Liana Tsikitis, Nima Nabavizadeh, Kim Lu, Charles R. Thomas, Timur Mitin
Journal: Journal of Clinical Oncology (2018)

e22120 Background: Current multimodality treatment of locally advanced rectal cancer (RC) includes chemotherapy, chemoradiation (CRT) and surgery. Growing clinical data suggest omitting resection (watch-and-wait) for patients (pts) with complete clinical response (cCR) to CRT with salvage resection for local recurrence, may lead to improved quality of life without jeopardizing oncological outcomes. The current acceptance of watch-and-wait by practicing US radiation oncologists (ROs) is unknown. Methods: US ROs completed our IRB-approved anonymous online survey regarding non-surgical management of pts who achieved cCR to neoadjuvant CRT. Self-ranked knowledge of the OnCoRe Project – a large national UK prospective observational study of watch-and-wait – was tested for its correlation with ROs’ attitudes using Chi-squared test. Supporters of observation are those who self-claimed their belief in observation. Results: Of the 220 responses, 61% of respondents practiced for over 10 years since completing residency with 48% (n = 106) supporting the wait-and-watch approach. Forty percent claimed familiarity with the OnCoRe Project publication. Respondents supporting observation were more likely to be familiar with the OnCoRe Project (p-value = 0.029). Among supporters of observation, 59% (n = 62) felt comfortable discussing the watch-and-wait approach and 41% preferred the conversation be initiated by other specialists. There was no association between comfort level in discussing non-surgical management and familiarity with the OnCoRe project. Yet, ROs treating more than 10 RC pts annually felt more more comfortable leading this discussion (p-value = 0.015) compared to ROs seeing fewer patients. Conclusions: Almost half of surveyed US ROs support the watch-and-wait approach, though many do not feel comfortable discussing this treatment paradigm with pts. Knowledge of the OnCoRe Project is associated with support of watch-and-wait, yet not comfort level in leading the discussion. These results inform provider attitudes toward participation in future clinical studies and guidelines in local RC management.
Effect of body mass index on chemotherapy-induced neutropenia in breast cancer.
Authors: Idris Yucel, Fatih Teker, Yasemin Kemal, Ahmet Siyar Ekinci, Bahiddin Yilmaz, Engin Kut
Journal: Journal of Clinical Oncology (2016)

e18218 Background: Standard treatment for early stage breast cancer (ESBC) consists of optimal surgery followed by adjuvant chemotherapy and/or hormonotherapy and/or radiotherapy. Doxorubicin and cyclophosphamide (AC) is a widely used chemotherapy schedule. An AC regimen carries intermediate risk for febrile neutropenia (approximately 3.3-12 %) and G-CSF prophylaxis is not routinely recommended. Nutritional status and body mass index (BMI) may influence the neutropenia risk. The aim of our study was to identify the impact of BMI on the development of neutropenia in ESBC patients during adjuvant chemotherapy. Methods: ESBC patients were retrospectively investigated for grade 3-4 neutropenia, febrile neutropenia and clinical characteristics of the sample were recorded. No primary prophylaxis was administered. Results: A total of 179 patients were eligible for analysis. All patients were chemotherapy naive. All patients completed 4 planned cycles of AC. During 716 cycles of primary chemotherapy 51 (28.4%) patients experienced chemotherapy induced neutropenia (CIN) and 5 (2.7%) patients had febrile neutropenia (FN). Patients with BMI < 30 kg/m2 had neutropenia occurrence at 38.6 % while BMI ≥ 30 kg/m2 was determined at 23.1 %. Patients with BMI > 30 kg/m2 BMI experienced less CIN than patients with BMI < 30 kg/m2 (p < 0.05)(Table). In this study population; age, family history, comorbidity, menopausal status, tumor size, nodal status, type of surgery, grade and absolute neutrophil count before chemotherapy were determined not to have affected the CIN risk (all p > 0,05). Conclusions: Although it is a retrospective study and includes a small number of patients we found that high BMI is associated with less CIN and FN. Future large scale studies are needed to evaluate this relationship. Neutropenia and BMI cross-tabulation. NEUTROPENIA Total YES NO BMI group Normal Count ( % ) 34 (38.60) 54 (61.40) 88 Obese Count (% ) 21 (23.10) 70 (76.90) 91 Total 55 124 179 OR (Normal / Obese) 95% Confidence Interval p 2.099 1,096 4,018 0,036
Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients.
Authors: Marios Giannakis, Haoxin Li, Chelsea Jin, Shuba Gopal, Kaushal Desai, Christine Horak, Megan Wind-Rotolo, Eliezer Mendel Van Allen, Clary Clish, F. Stephen Hodi, Levi A. Garraway, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2017)

3036 Background: Immune-checkpoint inhibition has been shown to be effective in a variety of cancers, including renal cell carcinoma (RCC) and melanoma. However, only a subset of patients with RCC and melanoma respond to anti-PD1 therapy. Given the importance of metabolism in the tumor immune microenvironment, we performed serum metabolomics in nivolumab-treated patients towards identifying novel non-invasive correlates of response and progression-free survival in immunotherapy-treated patients. Methods: We performed liquid chromatography-mass spectrometry on pre- and on-treatment serum samples from 79 patients with advanced melanoma (CA209-038 study) and 82 patients with metastatic RCC (CA209-009 study) receiving nivolumab. We precisely measured more than one-hundred named metabolites at baseline (prior to starting nivolumab), at 4 weeks and at 6 (melanoma) or 9 weeks (RCC) after initiation of treatment and correlated these with best overall response as well as progression-free survival (PFS). Results: In melanoma patients treated with nivolumab, the difference in mean levels of kynurenine (the product of IDO / TDO activity in tryptophan catabolism) between weeks 4 and 6 compared to baseline was significantly different between responders and non-responders (t-test with unequal variance p-value = 0.043 and p-value = 0.044 respectively). In RCC patients, we observed that patients with no response to nivolumab had significantly higher adenosine levels, than those who responded, at baseline and at 4 weeks after initiation of treatment (158% and 138% higher, t-test p-value = 0.0019 and p-value = 0.0011 respectively). RCC nivolumab-treated patients with higher (top quartile) baseline adenosine levels also had a significantly worse PFS (log rank test p-value = 0.004). Conclusions: In this first-of-its kind metabolomic analysis of peripheral blood from nivolumab-treated patients, we find that the change in kynurenine levels in melanoma patients correlates to response. In addition, higher baseline levels of adenosine in RCC patients are associated with worse PFS and lack of response to nivolumab. These results suggest a possible role for serum metabolites as biomarkers of benefit to PD1 inhibition.
Nasopharyngeal cancer in Alaska Native people: A cancer health disparity.
Authors: Matthew J. Olnes, Erik Pihl, Mariah Minder, Julia Clerc Parrish, Peter Holck, Jim Tiesinga, Barbara Stillwater, Garrett Zimpelman, Sarah Nash, Holly Martinson
Journal: Journal of Clinical Oncology (2018)

1574 Background: Cancer is a leading cause of death in Alaska Native (AN) people. Significant cancer health disparities exist in both incidence and mortality between AN people and the US Whites. Nasopharyngeal cancer (NPC) is the leading cancer disparity among AN people, with an incidence rate 17.3 times higher (2009-2013) and a mortality rate that is 21 times higher (1992-2011) than those in US whites. The etiologic basis for these disparities has not been identified. Methods: To better understand this health disparity, we created an Alaska Native NPC patient database derived from the Alaska Native Tumor Registry and Alaska Native Medical Center Tumor Registry to characterize all cases of NPC in AN people over the last forty years. We identified 186 cases of NPC in AN people from 1976 to 2016 by merging electronic data sets from the Alaska Native Medical Center Tumor Registry and the Alaska Native Tumor Registry, and analyzed, baseline demographics, clinical and pathologic features, patterns of care, and treatment outcomes for this disease for which data were available for analysis. Results: The median age of AN NPC patients was 60 years, and 68% of patients were male. The regions with the highest numbers of NPC were Anchorage/Mat-Su, followed by Yukon-Kuskokwim and Norton Sound regions of Alaska. The histologic subtype of NPC by World Health Organization category were 55% of tumors type 3, 25% type 1, and 15% type were type 2. Most AN patients with NPC presented at advanced AJCC TNM clinical stages at the time of diagnosis with 2% diagnosed at stage I, 10% at stage II, 9% at stage III, and 43% at stage IV. Patients were treated with chemotherapy (62%), radiation (69%), and combinations of chemotherapy and radiation (58%). Median survival for all patients was 2.5 years (95% Confidence Interval 1.9-3.0). Conclusions: This study represents the first characterization of NPC in AN people that includes treatment and clinical outcome data, and it may serve as a useful database to develop treatment guidelines and future translational studies to better understand this cancer health disparity.